Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSX-1004 Effects on Fentanyl-Induced Respiratory Depression
2025-524133-33-00Phase 2Authorised
- Sponsor
- Cessation Therapeutics
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of CSX1004 in opioid use disorder (OUD) (2 arms), sponsored by Cessation Therapeutics. Primary endpoint: Peak change in minute ventilation. Planned start Mar 2026; status: authorised.
02
Drugs
CSX1004
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on 2025-524133-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524133-33-00.